Cohort — Marching on

Cohort (AIM: CHRT)

Last close As at 21/11/2024

440.00

11.00 (2.56%)

Market capitalisation

GBP177m

More on this equity

Research: Industrials

Cohort — Marching on

Cohort has delivered better than-expected operating profit growth in FY18 as it continues to address the changing dynamics of its end markets. The company believes that the decline in the order book represents delays rather than a reduction in demand and, if this is the case, 2018/19 presents exciting business prospects. Cohort continues to invest and address new business areas while further acquisition presents an opportunity.

Analyst avatar placeholder

Written by

Industrials

Cohort

Marching on

FY18 results

Aerospace & defence

3 July 2018

Price

365p

Market cap

£149m

Net cash (£m) at 30 April 2018

11.3

Shares in issue

40.7m

Free float

70%

Code

CHRT

Primary exchange

AIM

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

4.3

3.6

(15.1)

Rel (local)

6.4

(3.0)

(17.7)

52-week high/low

430.0p

285.0p

Business description

Cohort is an AIM-listed defence and security company operating across four divisions: MASS (34% of FY18 sales); SEA (34%); MCL (16%); and the 80%-owned Portuguese business EID (17%).

Next events

AGM

July 2018

Analysts

Andy Chambers

+44 (0)20 3681 2525

Annabel Hewson

+44 (0)20 3077 5700

Cohort is a research client of Edison Investment Research Limited

Cohort has delivered better than-expected operating profit growth in FY18 as it continues to address the changing dynamics of its end markets. The company believes that the decline in the order book represents delays rather than a reduction in demand and, if this is the case, 2018/19 presents exciting business prospects. Cohort continues to invest and address new business areas while further acquisition presents an opportunity.

Year end

Revenue (£m)

PBT*
(£m)

EPS*
(p)

DPS
(p)

P/E
(x)

Yield
(%)

04/17

112.7

14.5

26.6

7.1

13.7

1.9

04/18

111.8

15.5

29.4

8.2

12.4

2.2

04/19e

118.4

16.0

31.2

9.2

11.7

2.5

04/20e

124.8

17.0

33.2

10.1

11.0

2.8

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items, share-based payments and one-off tax credits.

FY18 demonstrated performance improvement

FY18 reported a closing order book of £102.5m, down from the H118 report of £132.1m and FY17 £136.5m. The company cited delays for the lower order intake in the year. However, FY19 has a larger than normal concentration of opportunities, as expected orders have been delayed. Reported FY18 revenues were £111.8m (FY17: £112.7m), with all divisions reporting growth except for SEA, which is to undergo cost restructuring in FY19. Encouragingly, reported adjusted operating profit was £15.6m (FY17: £14.5m) up 8% with reported adjusted EPS (excluding one-off tax credits) up 10% at 29.4p (FY17: 26.6p). FY18 DPS was 8.2p (FY17: 7.1p), a 15.5% increase in line with the group’s progressive dividend policy. Net cash of £11.3m (FY17 £8.5m) was up from £5.7m at the half year, where a net cash flow had been expected on higher operating profit contribution.

Growth beyond within and across borders

While a UK defence review is in process, the overall pace of contracting at the MOD has yet to show any major signs of improvement. However, Cohort has been able to identify and serve new business areas. At the moment this is reflected in shorter-term contracts; however, the company is excited by the opportunities that 2018/19 presents both in the UK and export markets. Indeed, there appears to be a growing consensus that an increase in UK defence spending may be warranted, not just by the shortages in frontline and administrative personnel, but also because of varying and often resurgent threats. Cohort remains comparatively robust with the financial fire power to invest in its own businesses and pursue acquisitions.

Valuation: Premium to peers deserved

The average of our DCF and peer group SOP valuation approaches generates a fair value of 549p, an increase on our prior fair value of 508p. This fair value gives a 2019e P/E of 16.5x. Although Cohort is developing in line with expectations, it continues to trade on a FY19e P/E discount to its UK defence peers. In our view, such a discount to its peers is not warranted.

FY18 results

The salient features of the interim results are as follows:

Reported closing order book of £102.5m was down from the H118 report of £132.1m and FY17 £136.5m. The company cited delays for the lower order intake in the year. However, FY19 has a larger than normal concentration of opportunities, as the contracts expected in FY18 are pushed out into FY19.

Reported revenues were £111.8m (FY17: £112.7m).

Reported adjusted operating profit was £15.6m (FY17: £14.5m).

Reported adjusted EPS was 30.00p (FY17: 27.93p) including one-off tax credits.

Reported DPS was 8.2p (FY17: 7.1p), a 15.5% increase in line with the group’s progressive dividend policy.

Net cash of £11.3m (FY17 £8.5m) was up from £5.7m at the half year, where a net cash flow had been expected on higher operating profit contribution. Within the year the company paid £2.5m as the final payment on MCL and £3.5m on the 23% EID acquisition.

Exhibit 1: H1 and FY divisional analysis

April year end (£m)

H117

H217

FY17

H118

H218

FY18

FY % change

Order intake

MASS

32

29.1

(9.1)%

SCS*

3

SEA

31.4

27

(14.0)%

MCL

23.3

12.1

(48.1)%

EID

18.9

8.4

(55.6)%

Total order intake

108.6

76.6

-29.5%

Order book

MASS

49.4

42.6

40.9

(17.2)%

SCS*

SEA

44

41.4

33.1

(24.8)%

MCL

15.5

18.4

10.3

(33.5)%

EID

27.6

29.7

18.2

(34.1)%

Total order book

136.5

132.1

102.5

(24.9)%

Revenue

MASS

14.5

18

32.5

17.2

20.3

37.5

15.4%

SCS*

5

0

5

0

SEA

18

26.4

44.4

15.7

22.1

37.8

(14.9)%

MCL

7.9

6.9

14.8

5.1

12.3

17.4

17.6%

EID

4.6

11.4

16

6.8

12.3

19.1

19.4%

Total revenue

50

62.7

112.7

44.8

67

111.8

-0.8%

Adjusted operating profit

MASS

2.4

3.5

5.9

2.549

4.551

7.1

20.2%

SCS*

-0.5

0.0

-0.5

SEA

1.0

4.3

5.3

1.0

3.4

4.4

-16.9%

MCL

0.8

1.3

2.1

0.2

1.9

2.1

2.3%

EID

1.4

2.8

4.2

1.2

3.5

4.7

11.0%

HQ & Other

(1.3)

(1.2)

(2.5)

(1.3)

(1.4)

(2.7)

5.8%

Total adjusted operating profit

3.9

2.8

14.5

3.6

7.4

15.6

7.7%

Operating profit

(3.2)

4.2

1.0

0.8

9.2

10.0

Finance costs

0.0

0.0

0.0

0.0

(0.1)

(0.1)

Profit before tax

(3.2)

4.2

1.0

0.8

9.1

9.9

Tax expense

0.6

0.6

1.1

(0.1)

(1.3)

(1.4)

Net income

(2.7)

4.8

2.1

0.6

7.8

8.5

EPS (p) reported

6.0

3.1

9.1

6.3

13.6

19.9

118.6%

DPS (p)

2.2

4.9

7.1

2.55

5.65

8.2

15.5%

Net cash

8.5

8.5

5.7

11.3

32.9%

Source: Company reports. Note: *SCS business was restructured into MASS and SEA in December 2016.

Exhibit 2: FY18 defence and security revenue by market segment

Exhibit 3: FY18 defence and security revenue by end customer

Source: Company reports

Source: Company reports

Exhibit 2: FY18 defence and security revenue by market segment

Source: Company reports

Exhibit 3: FY18 defence and security revenue by end customer

Source: Company reports

MASS (FY18 sales: £37.5m; 34% of group sales) returned to growth. A key input was the completion of the biennial joint forces exercise, driving topline and margin. The division started deliveries to the Metropolitan Police Service for the Digital Forensics Programme, secured at the end of FY17. Lower electronic warfare operational support activity was countered by higher training support (ex SCS) and cyber volumes to increase the division operating margin.

SEA (FY18 sales: £37.8m; 34% of group sales) delivered a lower top-line result, as seen in the H118 report. The higher adjusted operating margin, up from 11.1% in FY16 reflects the higher export content and a trend towards more product sales. There is a natural lull between the completed design work on the Astute Class and the increased activity on Dreadnought Class, expected to last 18-24 months. To put this in context, the submarine revenue contribution was £21.1m in FY16 and just £7.3m in FY18. While the company is taking costs out of this area, it should be noted how successful the division has been to counter this decline with other business areas, including increased export sales of torpedo launch systems. In addition, the submarine communications programme has been considerably derisked and has allowed some contingency to be released. This division is also balancing the longer term contracts and the predictability that brings, with shorter term contracts within its simulation, support and product activity. While the ROADflow product range has seen growth, it experienced tough comparisons in H218 given the prior year peak. Given the reduced research and submarine activity, the business will face restructuring during FY19 at an anticipated cost of £0.5m, targeting annual savings of £1.0m per year.

EID (FY18 £19.1m; 17% of group sales) performance exceeded group expectations, with a higher naval contribution at 60% of the division, up from 30% last year. This is expected to move back in FY19 with lower naval support work and higher intercom and radio products. The company notes that the higher bought in element will bring the division’s expected operating margin levels close to 20%. Within the year, Cohort acquired an additional 23% of EID, taking the total holding to 80% as expected, enhancing future EPS.

MCL (FY18 sales £17.4m; 17% of group sales) delivered a flat performance, with increased volume and margin offset by slightly higher overheads. The company won a further £6m contract for hearing protection systems, building on the success of the business to date. Overall, MCL is moving to shorter-term order book visibility, of around three to six months on average.

Outlook

The current review and tightening of spending at the UK MOD is likely to have an ongoing impact on FY19 and beyond. However Cohort continues to broaden its exposure to different programmes and project areas. While the current order book stands at a lower level year-on-year, the company stresses this is due to contract delays rather than lack of demand. Outside the UK, Portugal is seeing a relatively robust level of spending with upgrades to maritime and land communication systems, from which EID should benefit. In addition, the company is well placed to leverage the growing requirement for defence and counter terrorism capability around the globe.

While FY18 order progression reflected delays, Cohort’s order book progression shows additional strength overall. Exhibit 4 gives a picture of the visibility of the order book across the divisions. Part of the strategy has been to stabilise and build visibility. Cohort’s delivery schedule does stretch out to 2025; however, order cover is typically in the range of 55-65% at the start of any given year. Cohort can also operate with an increasing level of shorter-term contracts, which can be supportive at the operating margin level but may not be visible in order book charts.

Exhibit 4: Delivery of the group’s order book into revenue

Source: Company reports

The company expects net cash to remain flat on FY18, as working capital is expected to rise to support contract work. However, beyond that the company expects cash contribution in FY20 to be strong, as the working capital unwinds. The group continues to be agile and will consider further suitable acquisitions.


Valuation

We continue to derive a fair value for Cohort from the simple average of a capped DCF and a peer-based group SOP. Our DCF approach generates a value of 550p (previous 529p) while our peer group SOP generates a value of 548p (previous 460p). This gives an average of 549p, an increase on our prior fair value of 508p. This reflects the uplift from moving our DCF on by one year but also, more significantly, the improvement in value of the peer group. This fair value gives a 2019e P/E of 16.5x. Although Cohort continues to develop in line with expectations, it continues to trade on a FY19e P/E discount to its UK defence peers. In our view, such a large discount is not warranted.

Exhibit 5: Peer group valuation sheet

Fiscal year end

Market Cap

Share Price

FX

FY1 PE

FY2 PE

FY1 EV/EBITDA

FY2 EV/EBITDA

FY1 EV/Sales

FY2 EV/Sales

FY1 Div Yield

FY2 Div Yield

COHORT PLC

CHRT LN

04/2018

149.5

365.0

GBP

11.7X

11.2X

8.6X

8.1X

1.21X

1.22X

2.5%

2.7%

BAE SYSTEMS PLC

BA/ LN

12/2017

20,437.1

640

GBP

14.7X

13.6X

9.6X

9.1X

1.15X

1.11X

3.5%

3.6%

CHEMRING GROUP

CHG LN

10/2017

636.7

227.5

GBP

17.8X

16.1X

9.0X

8.5X

1.43X

1.45X

1.4%

1.6%

COBHAM PLC

COB LN

12/2017

3,067.7

128.3

GBP

27.3X

19.4X

12.3X

11.2X

1.83X

1.80X

0.5%

1.7%

MEGGITT PLC

MGGT LN

12/2017

4,070.3

524.2

GBP

16.3X

15.2X

11.3X

10.5X

2.56X

2.44X

3.1%

3.3%

QINETIQ GROUP PLC

QQ/ LN

03/2018

1,535.5

270.4

GBP

15.8X

15.5X

8.6X

8.2X

1.51X

1.48X

2.4%

2.6%

ROLLS-ROYCE

RR/ LN

12/2017

18,228.4

975

GBP

65.4X

35.6X

13.9X

10.7X

1.25X

1.20X

1.3%

1.5%

ULTRA ELECTRONICS

ULE LN

12/2017

1,195.7

1611.000

GBP

14.7X

13.2X

10.1X

9.4X

1.70X

1.59X

3.1%

3.2%

Uk Average

24.6X

18.4X

10.7X

9.6X

1.6X

1.6X

2.2%

2.5%

AIRBUS SE

AIR FP

12/2017

75,810.6

97.7

EUR

21.8X

17.6X

8.6X

7.3X

1.02X

0.92X

1.8%

2.1%

FACC AG

FACC AV

02/2018

751.9

16.4

EUR

19.0X

15.4X

9.7X

8.4X

1.17X

1.06X

1.5%

2.1%

LATECOERE

LAT FP

12/2017

429.7

4.5

EUR

27.5X

14.7X

10.6X

6.7X

0.63X

0.61X

0.0%

0.7%

LEONARDO SPA

LDO IM

12/2017

4,838.0

8.4

EUR

10.7X

8.5X

5.4X

5.0X

0.73X

0.70X

1.7%

1.9%

MTU AERO ENGINES AG

MTX GR

12/2017

8,382.4

161.2

EUR

19.9X

18.5X

12.1X

11.4X

2.31X

2.00X

1.7%

1.9%

RHEINMETALL AG

RHM GR

12/2017

4,029.2

92.5

EUR

14.6X

12.6X

5.9X

5.3X

0.65X

0.60X

2.1%

2.4%

SAAB AB-B

SAABB SS

12/2017

40,047.3

366.9

SEK

21.4X

17.2X

12.2X

10.1X

1.27X

1.17X

1.7%

1.9%

SAFRAN SA

SAF FP

12/2017

45,388.5

102.3

EUR

22.8X

19.0X

12.3X

10.6X

2.18X

1.99X

1.7%

2.1%

THALES SA

HO FP

12/2017

23,196.7

109.0

EUR

20.7X

17.3X

9.8X

8.6X

1.29X

1.13X

1.8%

2.2%

19.8X

15.6X

9.6X

8.2X

1.3X

1.1X

1.6%

1.9%

Source: Bloomberg. Note: Priced at close 2 July 2018

Financials

While revenues were below expectations, margins have continued to deliver the operating performance expected. SEA is likely to improve profitability in the current year, with the £0.5m charge for restructuring being taken as an exceptional cost, with MASS and MCL continuing to grow and EID performing well despite some margin reduction. Overall our EBIT expectation is essentially unchanged.

In FY19 the company expects to invest in working capital in the current year. As a result, our pre-tax profit declines by 0.3% and with a slightly higher weighted average number of shares than we had anticipated our EPS stays flat against our previous forecast. It should be noted that the one-off tax credits (FY18 0.6p) in each of the last three years are not expected to continue.

We introduce our FY20 estimates, which show accelerating earnings performance and a significantly improved cash flow following the FY19 investment.

Exhibit 6: Revisions

Year to April (£m)

2018e

2018

 

2019e

2019e

 

2020e

 

Prior

Actual

% change

Prior

New

% change

New

Revenues

MASS

39.0

37.6

-3.8%

41.4

39.8

-3.8%

42.2

SEA

43.0

37.8

-12.0%

46.4

38.2

-17.7%

40.1

MCL

17.4

17.4

-0.2%

19.7

19.7

-0.2%

20.9

EID

19.5

19.1

-2.4%

20.7

20.8

0.4%

21.6

Total Group

119.0

111.8

-6.0%

128.2

118.4

-7.6%

124.8

 

 

 

 

 

 

 

EBITDA

16.6

16.7

0.4%

17.4

17.2

-1.0%

18.3

 

 

 

 

 

 

 

MASS

7.0

7.1

1.2%

7.4

7.6

2.1%

8.0

SEA

5.2

4.4

-14.0%

5.4

4.6

-15.6%

4.8

MCL

2.1

2.1

-0.9%

2.4

2.4

0.6%

2.5

EID

3.9

4.7

19.6%

3.7

4.4

17.1%

4.5

HQ Other and intersegment

-2.8

-2.7

-3.6%

-2.9

-2.8

-3.5%

-2.8

EBIT (Pre PPA amortisation)

15.4

15.6

1.4%

16.0

16.1

0.4%

17.1

 

 

 

 

 

 

 

Underlying PTP

15.4

15.5

0.8%

16.1

16.0

-0.3%

17.0

 

 

 

 

 

 

 

EPS - underlying continuing (p)*

29.1

30.0

3.0%

31.2

31.2

0.0%

33.2

DPS (p)

8.2

8.2

0.0%

9.0

9.2

2.2%

10.1

Net cash / (debt)

9.7

11.3

16.9%

17.3

11.9

-30.1%

24.7

Source: Company reports, Edison Investment Research estimates. Note: *EPS includes one-off tax credit in FY18.

Exhibit 7: Financial summary

£m

2016

2017

2018

2019e

2020e

Year end 30 April

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

112.6

112.7

111.8

118.4

124.8

Cost of Sales

(79.1)

(73.7)

(72.4)

(76.7)

(80.8)

Gross Profit

33.5

39.0

39.4

41.7

44.0

EBITDA

 

 

13.0

15.7

16.7

17.3

18.3

Operating Profit (before amort. and except).

11.9

14.5

15.6

16.1

17.1

Intangible Amortisation

(6.4)

(11.3)

(5.3)

(4.7)

(0.3)

Exceptionals

(0.3)

(2.3)

(0.3)

(0.5)

0.0

Other

0.0

0.0

0.0

0.0

0.0

Operating Profit

5.2

1.0

10.0

11.0

16.8

Net Interest

0.1

0.0

(0.1)

(0.1)

(0.1)

Profit Before Tax (norm)

 

 

12.0

14.5

15.5

16.0

17.0

Profit Before Tax (FRS 3)

 

 

5.3

1.0

9.9

10.9

16.7

Tax

0.1

1.1

(1.4)

(1.9)

(2.7)

Profit After Tax (norm)

11.2

12.8

13.1

13.5

14.3

Profit After Tax (FRS 3)

5.4

2.1

8.5

9.0

14.0

Average Number of Shares Outstanding (m)

40.6

40.4

40.7

40.7

40.7

EPS - fully diluted (p)

 

 

26.7

31.0

29.7

30.9

32.9

EPS - normalised (p)

 

 

27.2

31.5

30.0

31.2

33.2

EPS - (IFRS) (p)

 

 

12.7

9.1

18.6

20.3

32.6

Dividend per share (p)

6.0

7.1

8.2

9.2

10.1

Gross Margin (%)

29.8

34.6

35.2

35.2

35.2

EBITDA Margin (%)

11.5

13.9

15.0

14.6

14.7

Operating Margin (before GW and except.) (%)

10.6

12.9

14.0

13.6

13.7

BALANCE SHEET

Fixed Assets

 

 

59.7

60.6

54.9

49.9

49.2

Intangible Assets

49.5

50.6

45.3

40.7

40.4

Tangible Assets

10.2

9.9

9.6

9.2

8.8

Investments

0.0

0.0

0.0

0.0

0.0

Current Assets

 

 

54.0

56.3

60.7

80.1

89.9

Stocks

2.0

5.3

6.4

8.9

8.4

Debtors

27.3

37.8

32.9

40.9

41.2

Cash

23.1

12.0

20.5

29.5

39.5

Other

1.6

1.2

0.8

0.8

0.9

Current Liabilities

 

 

(40.1)

(39.7)

(38.1)

(29.3)

(31.1)

Creditors

(36.8)

(36.1)

(28.9)

(29.3)

(31.1)

Short term borrowings

(3.3)

(3.5)

(9.2)

0.0

0.0

Long Term Liabilities

 

 

(2.7)

(3.2)

(1.9)

(19.2)

(16.6)

Long term borrowings

(0.0)

(0.0)

0.0

(17.4)

(14.8)

Other long term liabilities

(2.7)

(3.2)

(1.9)

(1.9)

(1.9)

Net Assets

 

 

70.8

74.0

75.6

81.4

91.3

CASH FLOW

Operating Cash Flow

 

 

8.5

2.4

15.7

7.7

20.1

Net Interest

0.1

0.0

(0.1)

(0.1)

(0.1)

Tax

(1.8)

(1.7)

(2.4)

(2.6)

(2.7)

Capex

(1.0)

(0.9)

(0.7)

(0.8)

(0.8)

Acquisitions/disposals

(0.7)

(9.1)

0.0

0.0

0.0

Financing

(3.2)

0.5

(6.8)

0.0

0.0

Dividends

(2.2)

(2.5)

(3.0)

(3.5)

(3.9)

Net Cash Flow

(0.3)

(11.4)

2.6

0.8

12.6

Opening net debt/(cash)

 

 

(19.7)

(19.8)

(8.5)

(11.3)

(12.1)

HP finance leases initiated

0.0

0.0

0.0

0.0

1.0

Other

0.5

0.0

0.2

(0.0)

0.0

Closing net debt/(cash)

 

 

(19.8)

(8.5)

(11.3)

(12.1)

(25.7)

Source: Company reports, Edison Investment Research estimates. Note: *FY16, FY17, FY18 EPS include one-off tax credits

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cohort and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cohort and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Cohort

View All

Latest from the Industrials sector

View All Industrials content

Genkyotex — Ready to make a dent in the fibrosis market

Genkyotex has initiated a Phase II investigator-sponsored trial in patients with Type 1 diabetes (T1D) and kidney disease (DKD). Separately, it has announced the positive outcome of a safety review of its Phase II trial with GKT831 in patients with primary biliary cholangitis (PBC) with no adverse events or patient dropouts. Interim data have been pushed back slightly to autumn 2018 from mid-2018 and full data to H119 from end-2018 due to a slow rate of activation of a number of research centres. Additionally, the original deal with the Serum Institute of India Ltd (SIIL) has been expanded and Genkyotex is now eligible to an additional €100m in milestone payments plus royalties on sales. We include the DKD indication and the new terms with SIIL in our valuation, which is now €338.7m or €4.35/share.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free